India Biomarker Test Market Research Report By Application (Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Diseases), By Type of Test (Genetic Tests, Proteomic Tests, Metabolomic Tests, Microbiomic Tests), By Technology (Polymerase Chain Reaction, Mass Spectrometry, Immunoassays, Next-Generation Sequencing) and By End Use (Hospitals, Clinical Laboratories, Research Institutions, Pharmaceutical Companies)-Forecast to 2035

India Biomarker Test Market Overview

As per MRFR analysis, the India Biomarker Test Market Size was estimated at 1.2 (USD Billion) in 2023.The India Biomarker Test Market Industry is expected to grow from 1.5(USD Billion) in 2024 to 4.2 (USD Billion) by 2035. The India Biomarker Test Market CAGR (growth rate) is expected to be around 9.812% during the forecast period (2025 - 2035).

Key India Biomarker Test Market Trends Highlighted

The India Biomarker Test Market is witnessing significant growth driven by several key market drivers. The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is pushing the demand for biomarker testing.

Government initiatives focused on improving healthcare access and the rising number of health awareness programs are also contributing to this trend. Moreover, advancements in technology, particularly in genetic testing and personalized medicine, are enhancing the accuracy and reliability of biomarker tests, making them more appealing to healthcare providers and patients alike.

Opportunities to be explored in the India Biomarker Test Market primarily lie in the untapped potential of rural healthcare.Since a big segment of the population lives in rural regions, there is a lack of more sophisticated diagnostic biometric tests and diagnostic services. The need for infrastructural development in health care services has advocated for public-private partnerships, which in turn has enabled pioneering biometric tests to access wider populations.

Emerging trends indicate growing adoption of companion diagnostics that will facilitate guided therapy for patients. The Indian government has also been taking initiatives for increased research and development in biotechnology, which is expected to provide new biomarkers and tests in the near future.

Additionally, regulatory approvals are being streamlined to facilitate quicker access to these testing services. All these factors contribute to a transformative phase in the India Biomarker Test Market, marking a shift towards more personalized healthcare solutions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

India Biomarker Test Market Drivers

Rising Incidence of Chronic Diseases

The increase in the incidence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is a significant driver for the India Biomarker Test Market Industry. According to the Indian Council of Medical Research, approximately 1.16 million new cancer cases were registered in India in 2018, and projections indicate that this number could rise by 10% in the coming years.

In addition to cancer, the prevalence of diabetes is expected to double from about 50 million in 2015 to an estimated 109 million by 2035, as reported by the International Diabetes Federation.

As a result, there is a growing demand for biomarker-based testing to facilitate early detection, personalized medicine, and targeted therapies, which creates a robust market opportunity for companies like Roche Diagnostics and Thermo Fisher Scientific, who are actively investing in innovative biomarker assays to cater to this rising healthcare need.

Advancements in Genetic Research

Technological advancements and increased funding in genetic research are propelling the India Biomarker Test Market Industry forward. With the launch of the National Biotechnology Development Strategy, the Indian government aims to enhance biotechnology capabilities through Research and Development initiatives.

The increased focus on precision medicine is evident with the Indian government allocating significant funds to research institutions and collaborations with global biotech firms.This emphasis on genetic testing helps develop novel biomarkers that improve diagnostic accuracy and therapeutic strategies. For instance, organizations like Biocon and Bharat Biotech are pioneering research in biomarker discovery to address the healthcare challenges specific to the Indian population.

Increased Government Initiatives and Support

Government initiatives to improve healthcare infrastructure and promote diagnostics are playing a vital role in boosting the India Biomarker Test Market Industry. The Pradhan Mantri Ayushman Bharat Yojana aims to provide health coverage to over 500 million people, creating a demand for advanced diagnostic solutions, including biomarker tests.

The Ministry of Health and Family Welfare in India supports various public health initiatives, which are geared toward integrating advanced diagnostic techniques in public health settings.With increased spending on health infrastructure, it is anticipated that more hospitals and clinics will adopt biomarker tests, thereby driving market growth. Companies such as LabCorp and Quest Diagnostics see this as an opportunity to expand their footprint in India by collaborating with local healthcare providers.

Growing Awareness of Personalized Medicine

There is a rising awareness of personalized medicine among healthcare professionals and patients in India, which is significantly contributing to the growth of the India Biomarker Test Market Industry. Personalized medicine is defined as a medical model that customizes healthcare, with decisions being tailored to the individual patient.

The adoption of this approach has gained momentum due to initiatives like the 'Make in India' program, highlighting the need for innovation in healthcare.According to a report by the Indian Pharmaceutical Alliance, nearly 80% of practitioners believe there is potential in personalized therapies, leading to increased demand for biomarker testing. As companies like Dr. Reddy's Laboratories and Cipla invest in personalized healthcare solutions, the expansion in this segment is expected to enhance market prospects.

India Biomarker Test Market Segment Insights

Biomarker Test Market Application Insights

The India Biomarker Test Market is poised for substantial growth, particularly within the Application segment, which encompasses various critical areas such as Oncology, Cardiovascular diseases, Neurology, Infectious Diseases, and Metabolic Diseases. Each of these applications plays a vital role in the evolving landscape of personalized medicine, driving advancements in diagnostics and therapeutic strategies. Oncology represents a significant portion of the market, as biomarkers are increasingly used to identify cancer types, tailor treatments, and monitor disease progression, thus enhancing patient outcomes.

The growing prevalence of cancers in India, fueled by lifestyle changes and environmental factors, further underscores the importance of biomarker tests in this field. Cardiovascular diseases remain one of the leading causes of morbidity and mortality in India, with biomarkers becoming essential in risk stratification, early detection, and managing treatments. With the rising incidence of such diseases, there is a substantial push towards developing robust diagnostic tools that leverage biomarker data.

Neurology also presents a critical opportunity as biomarkers for neurodegenerative disorders like Alzheimer’s and Parkinson’s facilitate earlier diagnosis and improved management of these complex conditions. Infectious diseases are gaining increased attention, especially with recent global health challenges highlighting the need for rapid and accurate diagnostics that biomarker tests can provide. Moreover, the growing burden of metabolic diseases such as diabetes and obesity in India contributes to the demand for innovative biomarker applications to monitor disease progression and treatment efficacy.

The integration of advanced technologies, including genomic and proteomic profiling, in these applications emphasizes a shift towards precision health solutions in India. Moreover, supportive government initiatives aimed at enhancing healthcare infrastructure and increasing access to diagnostic services bolster the India Biomarker Test Market, particularly across these pivotal applications.

Overall, as the healthcare ecosystem prioritizes preventive care and personalized treatment, the Application segment in the India Biomarker Test Market showcases a promising trajectory aligned with both current health trends and the increasing financial investments in healthcare innovations.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Biomarker Test Market Type of Test Insights

The India Biomarker Test Market is significantly influenced by the various types of tests available, including Genetic Tests, Proteomic Tests, Metabolomic Tests, and Microbiomic Tests. Genetic Tests hold substantial importance as they aid in identifying genetic predispositions to diseases, allowing early interventions and personalized medicine approaches. Proteomic Tests, on the other hand, are pivotal in understanding protein expression in various conditions, which enhances disease diagnosis and therapy.

Metabolomic Tests contribute to the analysis of metabolic profiles and their links to health, providing insights into disease mechanisms.Similarly, Microbiomic Tests reveal the complexities of microbial communities, underscoring their role in disease and health management. The increasing occurrence of chronic diseases and the growing inclination towards personalized medicine in India are key factors propelling the demand across these test types.

Furthermore, the emphasis on Research and Development (R&D) and technological advancements is likely to further bolster the market dynamics, presenting significant opportunities for growth. As India progresses in healthcare innovation, the {Type of Test} segment plays a critical role in transforming clinical practices and improving patient outcomes.

Biomarker Test Market Technology Insights

The Technology segment of the India Biomarker Test Market plays a pivotal role in advancing diagnostic capabilities and treatment personalization. This segment encompasses various methodologies, with Polymerase Chain Reaction being widely recognized for its precision in amplifying DNA segments, crucial for early disease diagnosis.

Mass Spectrometry stands out for its ability to analyze complex biological samples, providing valuable insights into protein structures and functions, thus playing a critical role in biomarker discovery. Immunoassays offer a robust platform for detecting and quantifying antigens and antibodies, making them vital for disease monitoring and therapeutic efficacy assessment.

Next-Generation Sequencing has revolutionized genomics by enabling comprehensive analysis of genetic variations, significantly impacting personalized medicine and cancer treatment strategies.

As India progresses towards innovative healthcare solutions, these technologies are expected to be key drivers in the evolution of the biomarker test landscape, fostering improved healthcare outcomes and supporting the country's growing focus on Research and Development in the life sciences sector. The increasing emphasis on precision medicine and higher diagnostic accuracy further highlights the dominance of these technologies in the India Biomarker Test Market.

Biomarker Test Market End Use Insights

The End Use segment of the India Biomarker Test Market encompasses various critical stakeholders, including Hospitals, Clinical Laboratories, Research Institutions, and Pharmaceutical Companies. Hospitals are pivotal in driving the demand for biomarker tests due to their role in patient diagnosis and treatment monitoring, contributing significantly to overall healthcare delivery.

Clinical Laboratories act as essential service providers, processing a large volume of tests, thus ensuring rapid and accurate results for healthcare professionals. Research Institutions enhance the industry's growth by developing innovative biomarker solutions, focusing on enhancing disease understanding through detailed research.Pharmaceutical Companies leverage biomarker tests in drug development and personalized medicine, which is increasingly gaining traction as a vital strategy for precision therapies.

This growing focus on targeted therapies is expected to shape future market trends as stakeholders recognize the importance of biomarkers in improving patient outcomes and treatment efficacy. As a result, the India Biomarker Test Market segmentation reflects a dynamic interplay among these entities, continuously adapting to technological advancements and evolving user needs within the healthcare landscape.

India Biomarker Test Market Key Players and Competitive Insights

The India Biomarker Test Market is witnessing significant growth driven by advancements in technology, the increasing prevalence of chronic diseases, and the rising emphasis on personalized medicine. This market is characterized by a competitive landscape featuring numerous players who are striving to establish their presence through innovation and strategic collaborations.

The assessment of competitive insights reveals how companies are positioning themselves to capture market share through research and development, product offerings, and partnerships with healthcare providers. The dynamics involve understanding customer needs, regulatory challenges, and the overall demand for biomarker testing services and products, which is integral to diagnosing diseases and monitoring treatment responses.Agilent Technologies holds a significant place in the India Biomarker Test Market owing to its robust product portfolio and strong technological expertise.

The company is distinguished by its innovative solutions that enhance the accuracy and efficiency of biomarker tests. Agilent's commitment to advancing life sciences is evident in its focus on research and development, which allows it to stay ahead of the competition. With a well-established presence in India, Agilent Technologies offers a range of high-quality analytical instruments, reagents, and software solutions tailored for biomarker discovery and validation.

The reliability and precision of its products have bolstered its reputation within the market, making it a preferred choice among healthcare professionals and researchers in the region.Siemens Healthineers also commands a notable position in the India Biomarker Test Market, offering an extensive array of products and services designed to improve diagnostic capabilities.

The company's strengths lie in its advanced imaging and laboratory diagnostics solutions, which enable healthcare providers to effectively diagnose and monitor various medical conditions. Siemens Healthineers is strategically focused on innovation, consistently upgrading its technology to meet the evolving needs of the healthcare system in India.

The company has established strong partnerships and collaborations, contributing to its market presence and expanding its reach. Notably, Siemens Healthineers has also pursued mergers and acquisitions to enhance its service offerings and competitive edge. Its comprehensive portfolio, which includes advanced biomarker assays and diagnostic equipment, positions it favorably within the Indian market, highlighting its commitment to elevating healthcare standards through cutting-edge technology.

Key Companies in the India Biomarker Test Market Include

• Agilent Technologies


• Siemens Healthineers


• Luminex


• Merck KGaA


• QIAGEN


• BioRad Laboratories


• Novartis


• Thermo Fisher Scientific


• Illumina


• BD


• Roche


• Sysmex


• Celerion


• Abbott Laboratories


• PerkinElmer

India Biomarker Test Market Industry Developments

The India Biomarker Test Market is currently experiencing significant developments, driven by advancements in technology and increasing investments in healthcare diagnostics. Companies such as Thermo Fisher Scientific and Roche have expanded their product portfolios, enhancing capabilities in precision medicine and personalized therapy solutions, making them more accessible within the Indian healthcare framework.

In August 2023, Novartis announced a partnership with various Indian healthcare stakeholders to enhance biomarker research, aiming to integrate these tests into mainstream cancer therapies.Recent market growth has been notable, with reports indicating an increase in market valuation attributed to rising demand for early diagnosis and increased government initiatives focusing on healthcare improvement.

Major players, including Agilent Technologies and QIAGEN, are investing heavily in Research and Development within the region, which has led to an uptick in innovative testing solutions. In April 2023, BioRad Laboratories announced a strategic acquisition that strengthened its capabilities in biomarker testing specific to infectious diseases. Such strategic moves align with the growth trajectory, as stakeholders aim to leverage the increasing awareness and need for accurate biomarker diagnostics within India's evolving healthcare landscape.

India Biomarker Test Market Segmentation Insights

Biomarker Test Market Application Outlook

• Oncology


• Cardiovascular


• Neurology


• Infectious Diseases


• Metabolic Diseases

Biomarker Test Market Type of Test Outlook

• Genetic Tests


• Proteomic Tests


• Metabolomic Tests


• Microbiomic Tests


• Biomarker Test Market Technology Outlook


• Polymerase Chain Reaction


• Mass Spectrometry


• Immunoassays


• Next-Generation Sequencing

Biomarker Test Market End Use Outlook

• Hospitals


• Clinical Laboratories


• Research Institutions


• Pharmaceutical Companies

 

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	1.2(USD Billion)
MARKET SIZE 2024	1.5(USD Billion)
MARKET SIZE 2035	4.2(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	9.812% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Agilent Technologies, Siemens Healthineers, Luminex, Merck KGaA, QIAGEN, BioRad Laboratories, Novartis, Thermo Fisher Scientific, Illumina, BD, Roche, Sysmex, Celerion, Abbott Laboratories, PerkinElmer
SEGMENTS COVERED	Application, Type of Test, Technology, End Use
KEY MARKET OPPORTUNITIES	Rising prevalence of chronic diseases, Growing demand for personalized medicine, Advancements in genomic technologies, Increasing government healthcare funding, Expanding clinical trial activities in India
KEY MARKET DYNAMICS	Rising prevalence of chronic diseases, Increasing demand for personalized medicine, Growth in research and development funding, Advancements in technology and analytics, Government initiatives promoting precision medicine
COUNTRIES COVERED	India